This publication is a review article, pulls together all the work Resverlogix has been doing over the past couple years to make the case for apabetalone as a COVID treatment.  Submitted last December, and will be in print in April.  Note, all the authors work for resverlogix. 

But  is great to get published!  This reads to me like a scientific version of an investment pitch media  segment, getting the science out there, including to potential BP partner types?

My take,  FWIW